Zymeworks to transfer zanidatamab program to Jazz; Jazz acquires ZZI subsidiary

Zymeworks Inc.

On April 25, 2023, Zymeworks entered a Stock and Asset Purchase Agreement with Jazz Pharmaceuticals to transfer the zanidatamab program.
Jazz will acquire 100% of ZZI, a Zymeworks subsidiary focused on zanidatamab, and related assets and employees.
No Zymeworks common stock is sold; Jazz assumes responsibility for development and commercialization under an amended collaboration agreement.
Zymeworks retains rights to ZW49 (zanidatamab zovodotin) and will continue to supply zanidatamab to clinical sites.
Closing expected in May 2023; financial terms of the original collaboration agreement remain unchanged.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

Zymeworks Inc. entered into Stock and Asset Purchase Agreement with Jazz Pharmaceuticals, Inc. (effective 2023-04-25).

Action: entry
Agreement: asset purchase
Counterparty: Jazz Pharmaceuticals, Inc.
Effective: 2023-04-25

Exact text from the filing

On April 25, 2023, Zymeworks BC Inc. (“Zymeworks BC”), a subsidiary of Zymeworks Inc. (the “Company”), Zymeworks Biopharmaceuticals Inc. (“ZBI”), a subsidiary of Zymeworks BC, Zymeworks Zanidatamab Inc. (“ZZI”), a subsidiary of ZBI formed in December 2022 focused on the Company’s development program for the Company’s bispecific HER2 antibody product candidate known as zanidatamab, and Jazz Pharmaceuticals, Inc. (“Jazz”), entered into a Stock and Asset Purchase Agreement (the “Transfer Agreement”).

View on SEC.gov

24 material agreements filed in the last 30 days. Browse all material agreements →

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-116976

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.